

# Daniel Aletaha

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8190186/daniel-aletaha-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210  
papers

29,383  
citations

63  
h-index

171  
g-index

257  
ext. papers

36,586  
ext. citations

5.2  
avg, IF

7.21  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 210 | Reply.. <i>ACR Open Rheumatology</i> , <b>2022</b> ,   | 3.5  |           |
| 209 | The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,   | 2.4  | 0         |
| 208 | Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,                              | 2.4  | 10        |
| 207 | Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson .. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,                  | 2.4  |           |
| 206 | Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,   | 2.4  | 4         |
| 205 | The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,                | 9.5  | 2         |
| 204 | Reply to "Correspondence on "Re-examining remission definitions in RA: considering the DAS28, CRP level and patient global assessment" by Felson et al.". <i>Arthritis Care and Research</i> , <b>2021</b> ,   | 4.7  |           |
| 203 | Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , | 2.4  | 2         |
| 202 | Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4  | 5         |
| 201 | SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1355-1356  | 2.4  | 63        |
| 200 | Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis"' by Dumoulin. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4  |           |
| 199 | Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response"' by Westhoff. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e163  | 2.4  | 1         |
| 198 | Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102849  | 13.6 | 3         |
| 197 | Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 71-87   | 2.4  | 50        |
| 196 | EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 31-35   | 2.4  | 61        |
| 195 | Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 682-691  | 3.9  | 2         |
| 194 | Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211022533  | 3.8  | 1         |

|     |  |     |     |
|-----|--|-----|-----|
| 193 | Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , <b>2021</b> , 7,   | 5.9 | 1   |
| 192 | Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 884-890   | 2.4 | 5   |
| 191 | SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1345-1350  | 2.4 | 88  |
| 190 | EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,  | 2.4 | 6   |
| 189 | EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1286-1298  | 2.4 | 6   |
| 188 | Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , <b>2021</b> , 7,  | 5.9 | 2   |
| 187 | Message from the new EULAR President and Steering Group. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1266-1267   | 2.4 |     |
| 186 | Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e167   | 2.4 | 2   |
| 185 | A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , <b>2021</b> , 7, | 5.9 | 4   |
| 184 | In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. <i>RMD Open</i> , <b>2021</b> , 7,  | 5.9 | 2   |
| 183 | Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1519-1534   | 4.4 | 8   |
| 182 | Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 874-882  | 2.4 | 9   |
| 181 | Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,                                      | 2.4 | 1   |
| 180 | EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 700-712   | 2.4 | 238 |
| 179 | Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233781   | 3.7 | 15  |
| 178 | Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 643-644  | 5.3 | 2   |
| 177 | Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. <i>Patient Preference and Adherence</i> , <b>2020</b> , 14, 949-961  | 2.4 | 3   |
| 176 | Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?. <i>Lancet, The</i> , <b>2020</b> , 395, 1091-1093  | 4.0 |     |

|     |  |      |     |
|-----|--|------|-----|
| 175 | Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20933489  | 3.8  | 0   |
| 174 | Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 445-452  | 2.4  | 17  |
| 173 | Precision medicine and management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , <b>2020</b> , 110, 102405  | 5.5  | 22  |
| 172 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 685-699   | 3.4  | 851 |
| 171 | Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1227-1229   | 9.5  | 1   |
| 170 | 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,             | 2.4  | 11  |
| 169 | Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , <b>2020</b> , 6,  | 5.9  | 7   |
| 168 | Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , <b>2020</b> , 59, 1556-1565  | 3.9  | 7   |
| 167 | Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , <b>2020</b> , 108, 102379   | 15.5 | 12  |
| 166 | An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , <b>2020</b> , 59, 1842-1852  | 3.9  | 5   |
| 165 | A critical review of the reproductive safety of Leflunomide. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 607-612  | 3.9  | 3   |
| 164 | Genetic risk scores in inflammatory arthritis: a new era?. <i>Nature Reviews Rheumatology</i> , <b>2020</b> , 16, 545-548  | 4.1  | 2   |
| 163 | Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab" by Pethoe-Schramm. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , | 2.4  |     |
| 162 | Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 1405-1413   | 5.5  | 89  |
| 161 | Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 276-284  | 5.3  | 12  |
| 160 | Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 245-251  | 5.3  | 8   |
| 159 | Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Rheumatology</i> , <b>2020</b> , 59, 324-334                               | 3.9  | 16  |
| 158 | Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. <i>Nature Medicine</i> , <b>2020</b> , 26, 974-980  | 50.5 | 3   |

|     |   |      |     |
|-----|---|------|-----|
| 157 | The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 2091-2098  | 3.9  | 10  |
| 156 | Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. <i>Advances in Therapy</i> , <b>2019</b> , 36, 1672-1683  | 4.1  | 19  |
| 155 | To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e61   | 2.4  | 3   |
| 154 | Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. <i>Nature Reviews Rheumatology</i> , <b>2019</b> , 15, 633-634   | 8.1  | 22  |
| 153 | Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. <i>PLoS ONE</i> , <b>2019</b> , 14, e0219698  | 3.7  | 9   |
| 152 | Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <i>Rheumatic Disease Clinics of North America</i> , <b>2019</b> , 45, 315-324 | 2.4  | 1   |
| 151 | Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 231                            | 5.7  | 1   |
| 150 | Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 211-217   | 5.3  | 32  |
| 149 | Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1  | 2   |
| 148 | Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1609-1615  | 2.4  | 19  |
| 147 | Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , <b>2019</b> , 58, 1025-1033  | 3.9  | 4   |
| 146 | Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e54   | 2.4  | 0   |
| 145 | Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. <i>Rheumatology</i> , <b>2018</b> , 57, 969-976  | 3.9  | 4   |
| 144 | Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 18001  | 51.1 | 750 |
| 143 | The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 311-313  | 2.4  | 5   |
| 142 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 3-17                   | 2.4  | 320 |
| 141 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 174  | 5.7  | 15  |
| 140 | Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , <b>2018</b> , 4, e000756                                       | 5.9  | 8   |

|     |  |      |      |
|-----|--|------|------|
| 139 | EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , <b>2018</b> , 4, e000780   | 5.9  | 8    |
| 138 | Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , <b>2018</b> , 4, e000783   | 5.9  | 5    |
| 137 | Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1736-1741                           | 2.4  | 17   |
| 136 | Diagnosis and Management of Rheumatoid Arthritis: A Review. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 320, 1360-1372   | 27.4 | 596  |
| 135 | Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 401-414   | 5.3  | 8    |
| 134 | Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1705-1709  | 2.4  | 45   |
| 133 | Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , <b>2018</b> , 36, 4875-4879  | 4.1  | 21   |
| 132 | 2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 948-959  | 2.4  | 243  |
| 131 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 960-977   | 7.4  | 1649 |
| 130 | EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 491-496   | 2.4  | 125  |
| 129 | Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet, The</i> , <b>2017</b> , 389, 1206-1217 | 4.0  | 78   |
| 128 | Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 728-734  | 9.5  | 29   |
| 127 | Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 193-198  | 5.3  | 10   |
| 126 | Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- $\alpha$ inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. <i>ClinicoEconomics and Outcomes Research</i> , <b>2017</b> , 9, 451-458  | 1.7  | 5    |
| 125 | Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 689-697  | 3.9  | 18   |
| 124 | The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 2038-2045  | 2.4  | 23   |
| 123 | Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 720-727   | 9.5  | 12   |
| 122 | Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 518-528       | 9.5  | 13   |

|     |   |     |      |
|-----|---|-----|------|
| 121 | Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1479-85        | 2.4 | 47   |
| 120 | An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 791-795 | 2.3 | 25   |
| 119 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 16-22             | 2.4 | 156  |
| 118 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 3-15          | 2.4 | 814  |
| 117 | Management of rheumatoid arthritis: what happens and what does not happen in real life. <i>Rheumatology International</i> , <b>2016</b> , 36, 167-8                                   | 3.6 | 1    |
| 116 | Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study. <i>Rheumatology</i> , <b>2016</b> , 55, 41-8                           | 3.9 | 9    |
| 115 | Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 811-8      | 2.4 | 202  |
| 114 | The many faces of psoriatic arthritis - a challenge to treatment to target?. <i>Reumatologia</i> , <b>2016</b> , 54, 1-2  | 1.7 | 4    |
| 113 | Therapeutic implications of autoantibodies in rheumatoid arthritis. <i>RMD Open</i> , <b>2016</b> , 2, e000009  | 5.9 | 28   |
| 112 | Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1024-6                 | 4.1 | 3    |
| 111 | Rheumatoid arthritis. <i>Lancet, The</i> , <b>2016</b> , 388, 2023-2038   | 4.0 | 1794 |
| 110 | Fever of unknown origin (FUO) revised. <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 796-801   | 2.3 | 33   |
| 109 | Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, S45-S48  | 2.2 | 7    |
| 108 | Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 45, 167-73          | 5.3 | 39   |
| 107 | Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 963-9         | 2.4 | 27   |
| 106 | Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 891-7  | 4.7 | 268  |
| 105 | New insights into the measurement of disease activity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 268-72                                      | 5.3 | 6    |
| 104 | Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, e67           | 2.4 | 9    |

|     |   |     |      |
|-----|---|-----|------|
| 103 | Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 203   | 5.7 | 20   |
| 102 | Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 229   | 5.7 | 51   |
| 101 | Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , <b>2015</b> , 54, 994-1007  | 3.9 | 39   |
| 100 | 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 8-13   | 2.4 | 143  |
| 99  | Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 532-7   | 2.4 | 9    |
| 98  | Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , <b>2015</b> , 165, 3-9  | 2.9 | 65   |
| 97  | Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 276-89   | 8.1 | 265  |
| 96  | Classification of rheumatoid arthritis <b>2015</b> , 3-21   |     | 1    |
| 95  | Evaluation and outcomes of patients with rheumatoid arthritis <b>2015</b> , 790-801   |     | 1    |
| 94  | Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for Psoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S48-50  | 2.2 | 27   |
| 93  | Proposal for a new nomenclature of disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 3-5   | 2.4 | 155  |
| 92  | Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 794-802                     | 9.5 | 43   |
| 91  | Reply: To PMID 24757132. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 3245-6   | 9.5 |      |
| 90  | Cardiovascular risk factors and comorbidities in patients with hyperuricemia and/or gout: a systematic review of the literature. <i>Journal of rheumatology Supplement, The</i> , <b>2014</b> , 92, 9-14  |     | 20   |
| 89  | Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 328-35 | 2.4 | 182  |
| 88  | Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, R56  | 5.7 | 84   |
| 87  | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 492-509  | 2.4 | 1487 |
| 86  | Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 114-23  | 2.4 | 87   |



|    |  |     |     |
|----|--|-----|-----|
| 85 | How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients. <i>BioDrugs</i> , <b>2014</b> , 28 Suppl 1, S3-4  | 7.9 |     |
| 84 | Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1755-60  | 2.4 | 10  |
| 83 | Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2005-14   |     | 50  |
| 82 | Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 3-6  | 2.4 | 54  |
| 81 | Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 241-4   | 2.4 | 31  |
| 80 | Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 7-12  | 2.4 | 19  |
| 79 | EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 479-81  | 2.4 | 85  |
| 78 | Compression test (Gaenslen's squeeze test) positivity, joint tenderness, and disease activity in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 653-7  | 4.7 | 11  |
| 77 | Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 875-80  | 2.4 | 55  |
| 76 | Rheumatoid arthritis and falls: the influence of disease activity. <i>Rheumatology</i> , <b>2012</b> , 51, 2051-7  | 3.9 | 43  |
| 75 | Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1190-6   | 2.4 | 56  |
| 74 | Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2814-23   |     | 175 |
| 73 | Comparative effectiveness and safety of biological treatment options after tumour necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1303-8 | 2.4 | 88  |
| 72 | The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 235-43   | 8.1 | 70  |
| 71 | Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 687-93            | 2.4 | 94  |
| 70 | Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1702-5   | 2.4 | 81  |
| 69 | American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 404-13  | 2.4 | 518 |
| 68 | Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 252-8  | 5.3 | 24  |

|    |  |     |      |
|----|--|-----|------|
| 67 | Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 43-52                                     |     | 110  |
| 66 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 573-86                                  |     | 520  |
| 65 | Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3702-11                          |     | 99   |
| 64 | Patient-reported outcomes in chronic gout: a report from OMERACT 10. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1452-7   | 4.1 | 64   |
| 63 | Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. <i>Journal of rheumatology Supplement, The</i> , <b>2011</b> , 87, 54-8                             |     | 6    |
| 62 | Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2011</b> , 50, 381-8  | 3.9 | 81   |
| 61 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1631-40 | 2.4 | 48   |
| 60 | Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1975-80   | 2.4 | 42   |
| 59 | Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 733-9  | 2.4 | 115  |
| 58 | Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1999-2002   | 2.4 | 59   |
| 57 | Evaluation and outcomes of patients with rheumatoid arthritis <b>2011</b> , 941-954.e1   |     | 1    |
| 56 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 638-643   | 2.4 | 168  |
| 55 | Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 536-41   | 2.4 | 90   |
| 54 | Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 546-9  | 2.4 | 57   |
| 53 | Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 575-8   | 2.4 | 36   |
| 52 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 964-75   | 2.4 | 1210 |
| 51 | Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1441-7   | 2.4 | 182  |
| 50 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1589-95                | 2.4 | 117  |

|    |  |     |      |
|----|--|-----|------|
| 49 | Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 995-1003 | 2.4 | 108  |
| 48 | Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1058-64  | 2.4 | 79   |
| 47 | 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1580-8                             | 2.4 | 2158 |
| 46 | Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 631-7   | 2.4 | 1300 |
| 45 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2582-91                          |     | 182  |
| 44 | 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2569-81                                    |     | 4825 |
| 43 | Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology</i> , <b>2009</b> , 48, 1575-80   | 3.9 | 58   |
| 42 | A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , <b>2009</b> , 48, 1114-21   | 3.9 | 173  |
| 41 | Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. <i>BMC Musculoskeletal Disorders</i> , <b>2009</b> , 10, 41     | 2.8 | 33   |
| 40 | The use of data from early arthritis clinics for clinical research. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 117-23  | 5.3 | 7    |
| 39 | Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1242-9                                 |     | 99   |
| 38 | The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. <i>Rheumatic Disease Clinics of North America</i> , <b>2009</b> , 35, 759-72, viii  | 2.4 | 35   |
| 37 | Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, 112   | 5.7 | 7    |
| 36 | Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, 204  | 5.7 | 43   |
| 35 | Outcome Measurement in Rheumatoid Arthritis: Disease Activity <b>2009</b> , 225-230  |     | 1    |
| 34 | The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , <b>2008</b> , 10, 208  | 5.7 | 56   |
| 33 | Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). <i>International Immunology</i> , <b>2008</b> , 20, 861-8   | 4.9 | 157  |
| 32 | Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 238-43                                   | 2.4 | 58   |

|    |   |      |     |
|----|---|------|-----|
| 31 | Is computer-assisted management necessary for patients with early rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 338-9  |      |     |
| 30 | Monitoring disease activity in rheumatoid arthritis: an imperative. <i>Future Rheumatology</i> , <b>2008</b> , 3, 99-102  |      |     |
| 29 | Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2008</b> , 20, 306-13   | 5.3  | 27  |
| 28 | The importance of reporting disease activity states in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2622-31  |      | 39  |
| 27 | Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 3226-35   |      | 181 |
| 26 | The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2007</b> , 21, 663-75          | 5.3  | 100 |
| 25 | The health assessment questionnaire in routine clinical practice. <i>Nature Clinical Practice Rheumatology</i> , <b>2007</b> , 3, 122-3   |      | 1   |
| 24 | Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1284-8   | 2.4  | 72  |
| 23 | New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , <b>2007</b> , 370, 1861-74  | 4.0  | 706 |
| 22 | Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. <i>Arthritis Research and Therapy</i> , <b>2007</b> , 9, R72   | 5.7  | 28  |
| 21 | The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 377-8; author reply 378 |      | 11  |
| 20 | Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2784-92   |      | 205 |
| 19 | Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, 102   | 5.7  | 10  |
| 18 | The definition and measurement of disease modification in inflammatory rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , <b>2006</b> , 32, 9-44, vii  | 2.4  | 87  |
| 17 | Pre-arthritis: a concept whose time has come. <i>Future Rheumatology</i> , <b>2006</b> , 1, 1-4   |      | 6   |
| 16 | Early rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2006</b> , 18, 282-8  | 5.3  | 25  |
| 15 | Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. <i>Circulation</i> , <b>2005</b> , 111, 204-11   | 16.7 | 238 |
| 14 | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , <b>2005</b> , 7, R796-806                                       |      | 640 |

|    |  |      |     |
|----|--|------|-----|
| 13 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2005</b> , 28, 239-48   | 12.3 | 55  |
| 12 | Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 163-77  | 5.3  | 55  |
| 11 | Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2625-36   |      | 337 |
| 10 | Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2975-83   |      | 63  |
| 9  | The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 3333-6  |      | 37  |
| 8  | Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2016-24  | 4.1  | 116 |
| 7  | The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2005</b> , 23, S100-8                           | 2.2  | 375 |
| 6  | Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1269-75   | 2.4  | 40  |
| 5  | Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics. <i>Current Rheumatology Reports</i> , <b>2003</b> , 5, 409-12 | 4.9  | 7   |
| 4  | Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 1631-8   | 4.1  | 74  |
| 3  | Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity  |      | 15  |
| 2  | The sensitivity improved two-test algorithm BIT2 is a universal optimization strategy for SARS-CoV-2 serology  |      | 4   |
| 1  | Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial  |      | 7   |